(Q38105535)

28 August 2017

Ketamine as a new treatment for depression: a review of its efficacy and adverse effects (English)

1 reference

28 August 2017

4

1 reference

28 August 2017

Colleen K Loo

6

0 references

author name string

Natalie Katalinic

1

1 reference

PubMed ID

23661785

28 August 2017

Rosalyn Lai

2

1 reference

PubMed ID

23661785

28 August 2017

Andrew Somogyi

3

1 reference

PubMed ID

23661785

28 August 2017

Paul Glue

5

1 reference

28 August 2017

9 May 2013

1 reference

Australian and New Zealand Journal of Psychiatry

28 August 2017

1 reference

28 August 2017

47

1 reference

28 August 2017

8

1 reference

28 August 2017

710-727

1 reference

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

28 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Low dose ketamine increases prepulse inhibition in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The destruction of the lower urinary tract by ketamine abuse: a new syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Long-term dangers of ketamine anaesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine perturbs perception of the flow of time in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Changes in serum enzyme levels following ketamine infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Dose- and exposure-response to ketamine in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine: its mechanism(s) of action and unusual clinical uses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine in chronic pain management: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Clinical studies of induction agents. XXXVI: Ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine followed by memantine for the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Small-dose ketamine improves the postoperative state of depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine tolerance and hallucinations in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine-associated lower urinary tract destruction: a new radiological challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The use of a series of ketamine infusions in two patients with treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Acute and chronic effects of ketamine upon human memory: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

21 January 2018

Ketamine use: a review

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

A case of sustained remission following an acute course of ketamine in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Antidepressant effect of ketamine during ECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine cystitis as a mimic of carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Psychiatric safety of ketamine in psychopharmacology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Riluzole in the treatment of mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Selective cognitive impairments associated with NMDA receptor blockade in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine-associated ulcerative cystitis: a new clinical entity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Can ketamine prescribed for pain cause damage to the urinary tract?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Rapid response with ketamine on suicidal cognition in resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine-associated bladder dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

The STAR*D Project results: a comprehensive review of findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413486842

21 January 2018

Identifiers

DOI

10.1177/0004867413486842

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fypltjerszcanafvihcbhf4ntm

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_fypltjerszcanafvihcbhf4ntm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fypltjerszcanafvihcbhf4ntm

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/fypltjerszcanafvihcbhf4ntm